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specimens with SFC with sensitlwty 83% and specificity 86%. 
Conclusion IF at&=480 nm identifies SFC in plaques with high content of PG and SMC 
and in thin fibrous cap atheromas. 
ORAL CONTRIBUTIONS 
820 Novel Approaches to Percutaneous 
Coronary Intervention With Emphasis on 
Saphenous Vein Grafts 
Monday, March 31, 2003, 2!00 p.m.-3:30 p.m. 
McCormick Place, Room S401 
2:oo p.m. 
820-l A Prospective, Randomized Trial of 
Thromboatherectomy During Intervention of 
Thrombotic Native Coronary Arteries and Saphenous 
Vein Grafts: The X-TRACT Trial 
Grsqa W. Stone, David A. Cox, Joseph D. Babb, Dean Nukta, Luc Bilodeau, Louis 
Cannon, Thomas D. Stuckey, James Hermiller, Eric Cohen, Reginald Low, Alexandra J. 
Lansky, Steven R. Bailey, Richard E. Kuntz, Cardiovascular Research FoundationlLenox 
Hill Heart and Vascular Institute, New York, NY 
Background. Peri-procedural complications are increased during PCI of SVGs and 
native coronary arleries containing thrombus. Whether outcomes may be improved by 
thrombectomy prior to intervention is unknown. 
Methods. At 75 U.S. sites, 800 consecutive pts with diseased SVGs (72%) or native cor- 
onary lesions containing thrombus (28%) were prospectively randomized to standard 
PCI vs. thromboatherectomy with the ev3 X-SIZER followed by PCI. Randomization was 
stratified by Ilb/llla use. 
Results. Baseline clinical and angiographic characteristics were well matched, excepi 
that by core lab determination X-SIZER patients were more likely to have thrombus 
present (70% vs. 58%, p<O.OOl), and had a slightly greater initial diameter stenosis (70% 
vs. 67%, p-zO.05). GP Ilb/llla inhibitors were administered in 78% of each group. Rates of 
post procedure TIMI flow, no reflow and distal emboli were similar in the 2 groups. 
Among pts not receiving upfront Ilb/lila inhibitors, ball-out Ilb/llla use was required in 
fewer patients treated with the X-SIZER (2.1% vs. 10.3%, p=O.O2). The 30.day compos- 
ite major adverse cardiac event rate (death, MI, or TVR) was similar in pts treated with X- 
SIZER vs. control (17.0% vs. 17.4% respectively, p=NS). The X-SIZER did, however, 
lower the pre-specified rate of large Ml (Q-wave Ml or peak CPK-MB >8x nl) by 41% 
(5.5% vs. 9.6%, p=O.O3). After accounting for the difference in baseline thrombus and 
lesion severity by multwariate analysis, use of the X-SIZER was an independent predlc- 
tor of freedom from large Ml (odds ratio = 0.35, p=O.O02) and death or large Ml (OR = 
0.43, p&006). 
Conclusions. Performance of thromboatherectomy with the X-SIZER prior to PCI in dis- 
eased SVGs or thrombotlc native coronary lesions does not reduce the overall 30 day 
composite rate of adverse events. X-SIZER use does, however, reduce procedural com- 
plications as evidenced by less need for bail-out GP Ilb/llla inhibitors, and enhances 30. 
day survival free from large MI. 
2:15 p.m. 
820-2 Treatment of Saphenous Vein Bypass Grafts With 
Ultrasound Thrombolysis: A Randomized Study 
Mandeeo Sinoh Uri Rosenscheim. Kalon K. Ho, Peter B. Berger, Richard Kuntz, David 
R. Holmes, Jr., Mayo Clinic, Rochester, MN 
BackgroundPercutaneous coronary interventions (PCI) I” patients with saphenous vein 
grafts (SVG) have a high frequency of distal embolization and other adverse clinical 
events, particularly if thrombus is present. Acolysis (therapeutic ultrasound) has the abil- 
ity to break up thrombus in vitro, in animal models, and in humans. Whether this is bene- 
ficial during percutaneous SVG interventions is unknown. 
ObjectiveWe performed a randomized trial of Coronary Ultrasound Thrombolysis (CUT) 
in which patients with an acute coronary syndrome undergoing PCI in a SVG were ran- 
domly assigned to receive treatment with acolysis or therapy with abciximab. The pri- 
mary end point of study was a successful procedure without complications at 30 days 
defined as a final luminal diameter stenosis <30% by quantitative angiographic analysis 
with Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow and freedom from major 
adverse cardiac events (MACE- a composite of death, Q and non-Q-wave myocardial 
infarction, emergency bypass surgery, disabling stroke, and target lesion revasculariza- 
tron) at 30 days. 
Results. One hundred and eighty one patients, 92 randomized to acolysis and 89 to 
abciximab, were enrolled. The two groups were well matched for baseline and lesion 
characteristics. Angiographic procedural success was achieved in 83% of patients ran- 
domized to acolysis and 82% randomized to abciximab (p=O.O08). The cumulative inci- 
dence of MACE at 30 days was 25% I” the acolysis vs. 12% in the abciximab group 
(p=O.O38). due mainly to a greater frequency of non-Q-wave myocardial infarction 
(19.6% vs 7.9%, p=O.O3) in patients treated with acolysis. The incidence of Q-wave myo- 
cardial InfarctIon was also higher in patients treated with acolysis (5.4% vs 2.2%, p=NS). 
The primary end point was thus achieved in 53.8% of acolysis and 73.1% of abciximab 
patients (p=O.O14) 
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ConclusionsIn this randomized trial, use of therapeutic ultrasound in vein graft lesions 
in patients with acute coronary syndrome was associated with poor angiographic out- 
come and increased the incidence of acute ischemic complications. 
2:30 p.m. 
820-3 Predictors of Adverse Clinical Outcome in the 
Randomized Evaluation of Covered Stent in Saphenous 
Vein Graft (RECOVERS) Trial 
Goran Stank@& Antonio Colombo, Fabio Sgura, Flavio Airoldi, Carlo Briguori, 
Nicholaous Reifart, Patrizia Presbitero, Luigi Inglese. G. Heyndrickx, Carlo Di Mario, 
EM0 Centro Cuore Columbus, Milan, Italy. San Raffaele Hospital, Milan, Italy 
In the Randomized Evaluation of Covered Stent in Saphenous Vein Graft (RECOVERS) 
trial polytetrafluoroethylene (PTFE) covered stent was compared with stainless steel 
(SS) stent for prevention of major adverse cardiac events (MACE) for treatment of 
saphenous vein graft (SVG) lesions. The results of this trial have already been pre- 
sented. We aimed to determine clinical, angiographic and procedural predictors of 
adverse B-month clinical outcome. 
Methods and results: 292 pts ware randomized to PTFE JOSTENT (152 pts) and SS 
JOSTENT Flex (140 pts). Pts received aspirin and ticlopidine for 3 months. MACE were 
defined as death, myocardial infarction (Ml) and repeat revascularization. Cumulative 8- 
month MACE rate was 31% in PTFE group vs 19% in SS group (P=O.Ol), with Ml rate of 
14% vs 5.5% (P=O.O2). 
Multivariate analysis identified following predictors of Ml: prior stroke (coeff -2.46, 
P=O.O06), ref. vessel size (c&f. -1.52, P=O.O03), stent length (coeff. -0.11. P=O.O2), final 
min. lumen diameter (coeff 1.21, P=O.O3). Predictors of cumulative MACE were: use of 
PTFE stents (co& 0.78, P=O.O2), lesion length (coeff -0.05, PcO.02) and trend was 
found for COmDlianCs to 3-month ticlooidine theraov fceof 0.76. P=O.O9). Fioura shows 
. L .  I” 
calculated probability of MACE according to lesion length, compliance to 3 month ticlopi- 
dine therapy and use of PTFE stents. Conclusion: Use of PTFE covered stents to treat 
long SVG lesions and non-compliance to ticlopidine therapy negatively affects six-month 
clinical outcome 




A Prospective Randomized Multicenter Trial Comparing 
Distal Protection During Saphenous Vein Graft 
Intervention With a Filter-Based Device Compared to 
Balloon Occlusion and Aspiration: The FIRE Trial 
Greoa W. Stone, Campbell Rogers, James Hermiller, Robert Feldman, Patrick Hall, 
Robert Haber, A. Masud, Patrick Cambier, Ronald P. Caputo, Mark Turco, Richard 
Kovach, Bruce R. Brodie. Howard Herrmann. Richard Kuntz, Steve Ramee, David A. 
Cox, Cardiovascular Research FoundationlLenox Hill Heart and Vascular Institute, New 
York, NY 
Background. Percutaneous intervention (PCI) in diseased saphenous vain grafts (SVG) 
is associated with a high peri-procedural rate of complications. Distal protection dunng 
SVG PCI using a balloon occlusion and aspiration system (the PercuSurge GuardWire) 
has been shown in a large randomized trial to reduce 30 day MACE rates by 42%. Com- 
pared to balloon occlusion systems, filter-based distal protection devices may be simpler 
to use, and allow antegrade perfusion during the procedure, reducing ischemia time and 
facilitating intervention in pts with poor LV function. The absolute clinical efficacy of distal 
filters as an adjunct to PCI rn diseased SVGs has not been proven. however, nor has 
their relative efficacy compared to balloon occlusion/aspiration systems. 
Methods. We therefore performed a large, multicenter non-inferiority trial of PCI in dis- 
eased SVGs in which 650 consecutive pts at 65 U.S. and Canadian centers were ran- 
domized I:1 to intervention with distal protection using the BSC/EPI FillerWire EX vs. the 
PercuSurge GuardWire. The FilterWire consists of a microporous polyurethane net 
attached to a self-expanding nitinol ring anchored distally to a 0.014’ guidewire over 
which PCI is performed. Crossing profile is 3.9F. Randomization was stratified by use of 
Ilb/llla inhibitors, the administration of which was left to the discretion of the operators. 
The primary endpoint was the composite rate of death, Ml (CPK-MB z-3.x nl), CABG or 
target lesion revascularrzation at 30 days. 
Results. The last patient was enrolled in August, 2002. Pooling the pts, the mean age 
was 69+ 10 years, 21% were female, 31% had prior MI. 39% had diabetes, 82% hyper- 
tension, 86% hyperlipidemia, and 12% renal insufficiency. Baseline LVEF was 49% -+ 
12%. The mean graft age was 11 _+8 years. 
Conclusions. FIRE is the first completed large-scale randomized trial comparing filter- 
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based distal protection to balloon occlusion and aspiration during PCI of diseased saphe- 
nous vein grafts. The principle safety and efficacy data will be unblinded for presentation 
in March 2003. 
3:oo pm. 
820-5 Economic and Clinical Analysis of Elective 
Percutaneous Coronary Intervention Without On-Site 
Cardiac Surgery 
Kirsten Hall Lonq, Henry H. Ting, Erin K. MC Murky, Aaron S. Terry, Thomas H. 
Tiggelaar, Ryan J. Lennon, Kirk N. Garratt, Mandeep Singh, Charanjit S. Rihal, Douglas 
L. Wood, David Ft. Holmes, Mayo Clinic, Rochester, MN 
Background: Elective percutaneous coronary interventions (PCI) are routinely performed 
at hospitals with on-site cardiac surgery (CS). Smce 1999, elective PCI has been per- 
formed at lmmanuel St. Josephs Hospital (ISJ). a community hospital without on-site CS, 
with telemedicine support from Saint Matys Hospital (SMH). 
Methods: 215 PCI patients at ISJ were matched on clinical and lesion criteria to 430 PCI 
patients at SMH. Clinical outcomes assessed included procedural success (~20% resid- 
ual stenosis and without in-hospital death, myocardial infarction, coronary bypass sur- 
gery, or repeat PCI), and target vessel failure rates at 1 year (any death. myocardial 
infarction, or target vessel revascularization). Economic outcomes included billed 
charges for room and board, medications, supplies, laboratory, and hospital length of 
stay. 
Results: Procedural success rates were similar between groups (ISJ 99.0%; SMH 97%). 
Target vessel failure rates were also similar between groups at 1 year follow-up (ISJ 
16%; SMH 16%, P=O.80). Results of the economic comparison are shown in the table. 
Patients undergoing PCI at ISJ had significantly higher charges for medication and sup- 
plies reflecting higher utilization of stents (93% versus 86%) and glycoprotein Ilb/llla 
inhibitors (88% versus 57%). 
Conclusions: Favorable clinical outcomes can be achieved at a hospital without on-site 
CS at additional cost. Economic analyses are ongoing lo assess the relative cost-effec- 
tiveness of providing PCI without on-site CS. 
Economic Endpoints (2000 Constant Dollars) 
ISJ SMH Bootstrapped 95% Cl (mean P-value 
(mean) (mean) difference) 
Room and $2422 $2341 (-183, 346) 0.64 
Board 
Medications $2602 $1147 (1299, 1610) <o.ooo 
1 
Laboratory $1731 $1401 (164, 486) 0.0009 
Supplies 55013 53861 (698, 1564) 0.0001 
Length of Stay 2.34 days 2.23 days (-0.173, 0.378) 0.49 
3:15 p.m. 
820-6 Genetic Risk Diagnosis System for Restenosis After 
Percutaneous Coronary Intervention 
Hideo Izawa, Yoshiji Yamada, Hideki Horibe, Tomoko Kate, Sahoko Ichihara, Fumimaro 
Takatsu. Tovoaki Murohara. Mitsuhiro Yokota. Naaova Universitv Graduate School of 
Medicine, Nagoya, Japan, &if” International lnsti& of Biotechnology, Mitake, Japan 
Background: Although genetic epidemiological studies have suggested that several 
genetic variants increase the risk for restenosis after percutaneous coronary intervention 
(PCI), the genes that contribute to this condition remain to be identified definitively. Our 
aim was to develop a reliable system for genetic risk diagnosis of restenosis after either 
plain old balloon angioplasty (POBA) or stent implantation separately. 
Methods: Restenosis was evaluated for 1390 (910 in men, 480 in women) and 1001 
(710 in men, 291 in women) coronary lesions 6 months after successful POBA or stent 
implantation, respectively. The genotypes for 19 or 18 single nucleotide polymorphisms 
(SNPs). which we previously identified in an association study of 112 polymorphisms in 
71 genes with 445 patients with myocardial infarction and 464 controls, were determlned 
in men and women. respectively, with a fluorescence- or calorimetry-based allele-spe- 
cific DNA primer-probe assay system. 
Results: Multivariate logistic regression analysis with adjustment for age, body mass 
index, and the prevalence of smoking, hypertension, diabetes mellitus, hypercholester- 
olemia, and hyperuricemia revealed that six and five SNPs were associated with resteno- 
sis after POBA or stent implantation, respectively, both in men and in women. Combined 
genotype analysis yielded maximal odds ratios of 15.09 and 44.54 for restenosis after 
POBA and of 6.64 and 117.83 for in-stent restenosis in men and women, respectively. 
Conclusions: Ten and seven genes are susceptibility loci for restenosis after PCI in Jap- 
anese men and women, respectively, and the corresponding combined genotypes may 
prove reliable for determination of genetic risk for restenosis after POBA or stent implan- 
tation. This genetic risk diagnosis system is thus expected to contribute to the prediction 
of restenosis after PCI. 
ORAL CONTRIBUTIONS 
823 Percutaneous Intervention: Highlighted 
Biologic and Pharmacologic Adjuncts 
Monday, March 31,2003, 2:00 p.m.-3:30 p.m. 
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823-1 Improvement in Symptoms and Exercise Capacity at 
Eight Weeks in a Controlled Study of Autologous Bone 
Marrow Cell Transplant in Humans With Severe 
lschemic Heart Failure 
Emerson C. Perin, Hans F. Dohmann, Radovan Borojevic, Andre Luiz S. Sousa, Hans J. 
Dohmann. Antonio C. Carvalho. Yono J. Gena. Guilherme V. Silva. Fernando Ranael. 
Suzana A: Silva, Roberto Espo&atteT James ?. Willerson, Texas Heart Institute, _ 
Houston, TX, Hospital ProCardiaco, Rio de Janeiro, Brazil 
Background: Relatively limited treatment options exist for pts with severe ischemis heart 
failure (HF). We evaluated the safety and efficacy of transendocardial (TE) delivery of 
bone marrow mononuclear cells (BMNC) to treat pts with severe HF. 
Methods Fourteen pts (57.2 * 10.5 yrs, 11 males) with severe LV dysfunction by echo 
(EF 27 * 8 %) and severe CAD not amenable to revascularization were included. Pts 
were evaluated by exercise stress tests before and 8 wks after the procedure. Bone mar- 
row (5Oml) was aspirated from the iliac crests and BMNCs were isolated. TE injections 
were performed using the Myo-Star catheter (NOGA, Biosense) to target hibernating 
myocardium in IO pts. Four pts were followed without cell implants as a control group. 
Results: Events: There were no major in-hospital events. Minor events included tram 
sient hypotension with pulmonary congestion (n=l) and PVCs (n=l) on day 1. CK-MB 
levels did not increase in 24h. Late events in the BMSC group included 1 pt that had 
NSTMI at 7 days. In the Control group 1 pt died at 8 wks. Non-invasive F/U: In tie 
BMNC group NYHA functional class decreased from 2.2+0.8 to 1.2i0.4 compared to an 
increase 2.3+ to 2.5* in the control group (p<O.O004). Exercise times increased from 
7.45 * 1.97 to 9.002 0.2 min.in the treatment group vs. 7.42+0.48 to 4.26e2.00 in the 
control group. SPECT results will be presented. 
Conclusion: Preliminary results suggest that TE delivery of BMNCs is safe and feasible. 
In this high risk and small group of pts we have observed symptomatic benefit and 
improvement in treadmill exercise time. Further studies and follow-up are needed. 
2:15 p.m. 
823-2 Glycoproteln llla PIA Polymorphism and Early Outcome 
After Coronary Stenting in Patients With Adjunctive 
Abciximab Therapy 
Nicolas van Beckerath, Olga Gorchakova, Werner Koch, Julinda Mehilli, Petra 
Hoppmann, Adnan Kastrati, Albert Schomig, TV Mtinchen, Munich, Germany 
Background: d polymorphism of glycoprotein (GP) llla has been intensively investi- 
gated. We and others have reported that homozygous PI A2 carriage is associated with an 
increased risk of early thrombotic events following coronary artery stenting. In those 
studies only few or no patients had received abciximab. One purpose of this study was to 
test if the prothrombotic influence of the PI A2 allele afler coronary stenting persists in the 
presence of potent antiplatelet therapy with abciximab. The second purpose was to test 
whether PI A2 polymorphism that underlies most cases of alloimmunethrombocytopenia 
occurring in Caucasians is associated with thrombocytopenia in response to abciximab. 
Methods: Consecutive patients (n=2265) undergoing coronary stent implantation with 
adjunctive abciximab therapy were included in the study. Serial platelet counts were 
obtained (baseline, 6. 16. 24, 72h post intervention and before discharge) and in case of 
a platelet count -c 100 OOO/fl pseudothrombocytopenia was excluded or confirmed. GP 
llla PIA genotyping was performed with a TaqMan assay. Thrombotic events (death, 
myocardial infarction and stent thrombosis) were recorded during the first 30 days follow- 
ing stent implantation. Acute profound thrombocytopenia was defined as a true drop in 
platelet count to < 20 OOOifl within 24h. 
Results: The overall genotype distribution was 2.8% PlA*‘A2. 26.7% PiAziA’ and 70.5% 
Fi”““‘, Early thrombotic events were observed in 4.8% of PIAZ’*‘, 5.0% of PlA2IA’ and 
5.4% of PIA”A’ patients (P=O.EE). Acute profound thrombocytopenia developed in 14 
patients (I PlA2’A2. 7 FlA21A’ and 6 PIA’“‘). Thus, carrying PlA2was afflicted with a three- 
fold increase of the risk to develop acute profound thrombocytopenia (OR 3.2 [95% Cl, 
1 1 I-9.301). 
Conclusions: Adjunctive abciximab therapy appears to eliminate the previously 
described prothrombotic influence of the PI w allele in the setting of coronary stenting. 
Plm carriers, though, have an increased risk lo develop acute profound thrombocylope- 
nia in response to this therapy. 
